2 completed. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Algernon Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease NP-120 (Ifenprodil) - COVID | Phase 2 / Phase 3 | Completed | Algernon Pharmaceuticals | 168 | 2020-08-05 | 2021-12-03 |
| Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough Ifenprodil - Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Algernon Pharmaceuticals | 20 | 2020-07-29 | 2022-07-19 |
Cough (1) · Idiopathic Pulmonary Fibrosis (1)
ifenprodil (2)
Australia (2) · New Zealand (1) · Philippines (1) · Romania (1) · United States (1)